This announcement details the adjustment of the exercise price for the company's 2023 stock appreciation rights incentive plan. The exercise price has been set at 16.90 CNY per share. The adjustments are based on the company's performance and are intended to align with market conditions. The plan aims to incentivize employees while ensuring compliance with relevant regulations.
Summary generated by AI · Always verify with source document
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") announces the following regarding the adjustment of the exercise price of the 2023 stock appreciation rights incentive plan:
On December 5, 2023, the Company convened the 19th meeting of the eighth board of directors, which approved the "2023 Stock Appreciation Rights Incentive Plan (Draft)" and its summary. The plan and the related management measures were also approved.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.